Fakeng Liu1, Yuan Liu2, Xiuju Liu3, Kaisheng Mao4, Diansheng Zhong5, Adam I Marcus6, Fadlo R Khuri7, Shi-Yong Sun8, Yulong He9, Wei Zhou10. 1. Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, 30322, USA; Department of Gastrointestinal Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, PR China. Electronic address: Fakeng.liu@sanofi.com. 2. Department of Biostatistics and Bioinformatics, Emory University Rollins School of Public Health, Atlanta, GA, 30322, USA. Electronic address: yliu31@emory.edu. 3. Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, 30322, USA. Electronic address: xliu6@emory.edu. 4. Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, 30322, USA. Electronic address: kaisheng.mao@genetronhealth.com. 5. Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin, PR China. Electronic address: zhongdsh@hotmail.com. 6. Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, 30322, USA. Electronic address: aimarcu@emory.edu. 7. Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, 30322, USA. Electronic address: fkhuri@emory.edu. 8. Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, 30322, USA. Electronic address: ssun@emory.edu. 9. Department of Gastrointestinal Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, PR China. Electronic address: heyulong@mail.sysu.edu.cn. 10. Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, 30322, USA; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, 30322, USA. Electronic address: wzhou2@emory.edu.
Abstract
OBJECTIVE: We previously postulated that 2-deoxyglucose (2-DG) activates multiple pro-survival pathways through IGF1R to negate its inhibitory effect on glycolysis. Here, we evaluated whether IGF1R inhibitor synergizes with 2-DG to impede the growth of non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: The activation of IGF1R signaling was assessed by the phosphorylation of IGF1R and its downstream target AKT using immunoblot. Drug dose response and combination index analyses were carried out according to the method of Chou and Talalay. Flow cytometry was used to evaluate cell cycle progression. Apoptosis was monitored by caspase-3/PARP cleavages or Annexin V staining. A subcutaneous xenograft model was used to assess this combination in vivo. RESULTS: 2-DG induces the phosphorylation of IGF1R in its kinase domain, which can be abolished by the IGF1R inhibitor BMS-754807. Furthermore, the combination of 2-DG and BMS-754807 synergistically inhibited the survival of several non-small cell lung cancer (NSCLC) cell lines both in vitro and in vivo. The mechanistic basis of this synergy was cell line-dependent, and LKB1-inactivated EKVX cells underwent apoptosis following treatment with a subtoxic dose of 2-DG and BMS-754807. For these cells, the restoration of LKB1 kinase activity suppressed apoptosis induced by this combination but enhanced G1 arrest. In H460 cells, the addition of 2-DG did not enhance the low level of apoptosis induced by BMS-754807. However, treatment with 0.75 μM of BMS-754807 resulted in the accumulation of H460 cells with 8n-DNA content without affecting cell density increases. Hence, H460 cells may escape BMS-754807-induced G2/M cell cycle arrest through polyploidy. The inclusion of 2-DG blocked formation of the 8n-DNA cell population and restored G2/M phase cell cycle arrest. CONCLUSION: The combination of 2-DG and IGF1R inhibitor BMS-754807 may be used to suppress the proliferation of NSCLC tumors through different mechanisms.
OBJECTIVE: We previously postulated that 2-deoxyglucose (2-DG) activates multiple pro-survival pathways through IGF1R to negate its inhibitory effect on glycolysis. Here, we evaluated whether IGF1R inhibitor synergizes with 2-DG to impede the growth of non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: The activation of IGF1R signaling was assessed by the phosphorylation of IGF1R and its downstream target AKT using immunoblot. Drug dose response and combination index analyses were carried out according to the method of Chou and Talalay. Flow cytometry was used to evaluate cell cycle progression. Apoptosis was monitored by caspase-3/PARP cleavages or Annexin V staining. A subcutaneous xenograft model was used to assess this combination in vivo. RESULTS:2-DG induces the phosphorylation of IGF1R in its kinase domain, which can be abolished by the IGF1R inhibitor BMS-754807. Furthermore, the combination of 2-DG and BMS-754807 synergistically inhibited the survival of several non-small cell lung cancer (NSCLC) cell lines both in vitro and in vivo. The mechanistic basis of this synergy was cell line-dependent, and LKB1-inactivated EKVX cells underwent apoptosis following treatment with a subtoxic dose of 2-DG and BMS-754807. For these cells, the restoration of LKB1 kinase activity suppressed apoptosis induced by this combination but enhanced G1 arrest. In H460 cells, the addition of 2-DG did not enhance the low level of apoptosis induced by BMS-754807. However, treatment with 0.75 μM of BMS-754807 resulted in the accumulation of H460 cells with 8n-DNA content without affecting cell density increases. Hence, H460 cells may escape BMS-754807-induced G2/M cell cycle arrest through polyploidy. The inclusion of 2-DG blocked formation of the 8n-DNA cell population and restored G2/M phase cell cycle arrest. CONCLUSION: The combination of 2-DG and IGF1R inhibitor BMS-754807 may be used to suppress the proliferation of NSCLC tumors through different mechanisms.
Authors: Mark D Wittman; Joan M Carboni; Zheng Yang; Francis Y Lee; Melissa Antman; Ricardo Attar; Praveen Balimane; Chiehying Chang; Cliff Chen; Lorell Discenza; David Frennesson; Marco M Gottardis; Ann Greer; Warren Hurlburt; Walter Johnson; David R Langley; Aixin Li; Jianqing Li; Peiying Liu; Harold Mastalerz; Arvind Mathur; Krista Menard; Karishma Patel; John Sack; Xiaopeng Sang; Mark Saulnier; Daniel Smith; Kevin Stefanski; George Trainor; Upender Velaparthi; Guifen Zhang; Kurt Zimmermann; Dolatrai M Vyas Journal: J Med Chem Date: 2009-12-10 Impact factor: 7.446
Authors: B S Dwarkanath; F Zolzer; S Chandana; T Bauch; J S Adhikari; W U Muller; C Streffer; V Jain Journal: Int J Radiat Oncol Biol Phys Date: 2001-07-15 Impact factor: 7.038
Authors: Erich Hellemann; Jennifer L Walker; Mitchell A Lesko; Dakshayini G Chandrashekarappa; Martin C Schmidt; Allyson F O'Donnell; Jacob D Durrant Journal: PLoS Comput Biol Date: 2022-03-02 Impact factor: 4.475